Stay updated on Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.

Latest updates to the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedThe page has been updated to reflect the termination of a study involving Fruquintinib and Tislelizumab, with new dates and availability information for these drugs in the U.S.SummaryDifference4%
- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check46 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check53 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check67 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
- Check75 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.3%
Stay in the know with updates to Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.